SEARCH

SEARCH BY CITATION

References

  • 1
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. II): 11437.
  • 2
    Camilleri M & Choi M-G. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 3
    Everhart J & Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 9881005.
  • 4
    Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and the United Kingdom. Digestion 1999; 60: 7781.
  • 5
    Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 224853.
  • 6
    Camilleri M & Williams DE. Economic burden of irritable bowel syndrome: proposed strategies to control expenditures. Pharmacoeconomics 2000; 17: 3318.
  • 7
    Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Clin Gastroenterol 1999; 13: 46171.
  • 8
    Schmulson M, Lee O-Y, Chang L, Naliboff B, Mayer E. Symptom differences in moderate to severe IBS patients, based on predominant bowel habit. Am J Gastroenterol 1999; 94: 292935.
    Direct Link:
  • 9
    Whitehead WE & Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115 (5): 126371.
  • 10
    Drossman DA & Thompson WG. Irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992; 116: 100916.
  • 11
    Bockaert J, Fagni L, Dumuis A. 5-HT4 receptors: an update. In: Baumgarten HH, Göthert M, eds. Handbook of Experimental Pharmacology. Serotoninergic Neurons and 5-HT Receptors in the CNS. Berlin, Heidelberg, New York: Springer-Verlag, 1997: 129, 439–74.
  • 12
    Hegde SS & Eglen RM. Peripheral 5-HT4 receptors. FASEB J 1996; 10 (12): 1398407.
  • 13
    Grider JR, Foxx-Orenstein AE, Jin J-G. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 37080.
  • 14
    Schikowski A, Mathis C, Thewißen M, Ross H-G, Pak MA, Enck P. Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist. Gastroenterology 1999; 116 (4): A643A643, G2805G2805.
  • 15
    Coelho AM, Rovira P, Fioramonti J, Bueno L. Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology 2000; 118 (4)(Suppl. 2): A835A835, 43934393.
  • 16
    Buchheit KH, Gamse R, Giger R, et al. The serotonin 5-HT4 receptor. 2. Structure–activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995; 38: 23318.
  • 17
    Pfannkuche HJ, Buhl T, Gamse R, Hoyer D, Mattes H, Buchheit KH. The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastroenterol Motil 1995; 7: 280280.
  • 18
    Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280: 12706.
  • 19
    Fioramonti J, Million M, Bueno L. Investigations on a 5-HT4 receptor agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology 1998; 114: A752A752, G3103G3103.
  • 20
    Appel S, Kumle A, Hubert M, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997; 62 (5): 54655.
  • 21
    Degen L, Matzinger D, Merz M, Appel S, Maecke H, Beglinger C. The 5-HT4 receptor agonist tegaserod (HTF 919) accelerates upper and lower gastrointestinal (GI) transit. J Gastroenterol Hepatol 2000; 15: A441A441 (Abstract).
  • 22
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118 (3): 4638.
  • 23
    Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5 (2): 7591.
  • 24
    Lefkowitz M, Rüegg P, Dunger-Baldauf C, Shi Y. Validation of a global relief measure in clinical trials of irritable bowel syndrome with tegaserod. Gastroenterology 2000; 188(4) (Suppl. 2): A145A145, 855855.
  • 25
    Talley NJ, Nyrén O, Drossman D, et al. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int 1993; 6: 189211.
  • 26
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister A. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): 6977.
  • 27
    Hawkey CJ. Irritable bowel syndrome clinical trial design: future needs. Am J Med 1999; 107: 98102.
  • 28
    Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 23241.
  • 29
    Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107: 917.
  • 30
    Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994; 39 (6): 11718.
  • 31
    Karaus M & Wienbeck M. Colonic motility in humans: a growing understanding. Baillieres Clin Gastroenterol 1991; 5 (2): 45378.
  • 32
    Kellow JE, Delvaux M, Azpiroz F, Camilleri M, Quigley EM, Thompson DG. Principles of applied neurogastroenterology: physiology/motility-sensation. Gut 1999; 45(Suppl. 2): II1724.
  • 33
    McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in intestinal motility disorders. Drugs 1988; 36 (6): 65281.
  • 34
    Müller-Lissner SA. Treatment of chronic constipation with cisapride and placebo. Gut 1987; 28: 10338.
  • 35
    Van Outryve M, Milo R, Toussaint J, Van Eeghem P. ‘Prokinetic’ treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13(1): 4957.
  • 36
    Schütze K, Branstätter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11(2): 38794.
  • 37
    Drossman DA, Richter JE, Talley NJ, et al. Functional bowel disorders and functional abdominal pain. In: Drossman DA, ed. The Functional Gastrointestinal Disorders: Diagnostic, Pathophysiology, and Treatment—A Multinational Consensus, 1st edn. Virginia: Degon Associates, 1994: 136–7.
  • 38
    Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 7658.
  • 39
    Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisapride-induced prolongation of cardiac action potential and early after depolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 13779.